初治IDH突变胶质瘤围手术期IDH抑制:一项先导试验
这项单臂、开放标签、可行性围手术期试验纳入10例初治IDH1突变低级别胶质瘤患者,术前给予safusidenib(AB-218/DS-1001b),中位随访14个月。主要终点显示两阶段围手术期试验可行且可接受;1例发生手术相关严重不良事件,10例报告safusidenib相关不良事件,多为1级,1例3级转氨酶升高。肿瘤2-羟基戊二酸定量显示靶点活性,并与分化程序和神经兴奋性改变相关。
要点
- 围手术期给予safusidenib的兩阶段试验设计可行且可接受,已入组10例并完成围手术期部分。
- safusidenib相关不良事件多数为1级,1例出现3级转氨酶升高;另1例发生手术相关严重不良事件。
- 肿瘤2-羟基戊二酸定量显示靶点活性,伴分化程序与神经兴奋性改变。
核心结论
- 围手术期mIDH抑制方法安全可行,可作为胶质瘤药物开发的理念验证,并广泛用于临床试验设计。
- 研究对胶质瘤中mIDH抑制相关观察进行了详细探究。
研究设计与样本
- 单臂、开放标签、可行性围手术期试验,纳入初治IDH1突变低级别胶质瘤患者,术前给予safusidenib(AB-218/DS-1001b),一种口服小分子mIDH1抑制剂。
- 截至2024年11月8日,10例患者入组并完成围手术期部分,中位随访14个月;患者术后继续safusidenib并持续随访安全性和疗效。
- 主要终点为两阶段围手术期试验的可行性及可接受性。
主要发现
- 1例患者发生手术相关严重不良事件,10例报告safusidenib相关不良事件,多数为1级,1例发生3级转氨酶升高。
- 肿瘤2-羟基戊二酸定量显示靶点活性,与分化程序和神经兴奋性改变相关,并在事后分析中通过膜片钳电生理功能验证。
临床怎么用
- 作者认为该围手术期方法安全可行,可广泛应用于临床试验设计,作为推进胶质瘤药物开发的理念验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutant isocitrate dehydrogenase (mIDH) inhibition significantly improves progression-free survival in patients with mIDH WHO grade 2 glioma; however, a large proportion of patients will progress, and mechanisms of adaptation to mIDH inhibition remain poorly understood. Perioperative studies with evaluation of paired pre- and post-treatment samples enable detailed understanding of drug response, facilitating biomarker development, but are rare in glioma owing to safety and cost concerns. Here we conducted a single-arm, open-label feasibility perioperative trial in patients with mIDH1 low-grade glioma, treatment naive to radiation and chemotherapy, with safusidenib (AB-218/DS-1001b), an orally available small-molecule inhibitor of mIDH1. As of 8 November 2024, 10 patients were enrolled and have completed the perioperative component, with a median follow-up of 14 months. Patients continue postoperative safusidenib with ongoing follow-up for safety and efficacy. The primary endpoint showed the feasibility and acceptability of conducting a two-stage perioperative trial. One patient experienced a serious surgery-related adverse event, and ten reported safusidenib-related adverse events; most were grade 1, and one experienced grade 3 elevation of transaminases. Tumor 2-hydroxyglutarate quantification revealed on-target activity, associated with alterations in differentiation programs and neural excitability, functionally validated in post hoc analysis by patch-clamp electrophysiology. Taken together, these results provide a detailed investigation of observations associated with mIDH inhibition in glioma. The study shows the safety and feasibility of this perioperative approach, which can be applied broadly in clinical trial design, serving as proof of concept for advancing drug development in glioma. ClinicalTrials.gov registration: NCT05577416 .
引用
- Drummond KJ, Spiteri M, Cain SA, et al. Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial. Nat Med. 2025. PMID: 40841487. doi:10.1038/s41591-025-03884-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。